Flexion Therapeutics Inc (FLXN) 18.77 $FLXN
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 17, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
FLXN: 18.77 (-0.78), NDQ.TO: 15.30 (-0.49), XPLR: 6.14 (-0.04), JOUT: 32.20 (-0.19), NVDQ: 12.43 (-0.37), SPKE: 12.97 (+0.09)
Flexion Therapeutics to Present at 14th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 08, 7:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:50 a.m. Eastern Time at The Westin NY Grand Central Hotel in New York, NY.
FLXN: 18.77 (-0.78)
Flexion Therapeutics reports FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 5:51AM CDT
FLXN: 18.77 (-0.78)
Flexion Therapeutics' (FLXN) CEO Mike Clayman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 23, 9:13PM CDT
FLXN: 18.77 (-0.78)
Flexion Reports Year-End 2014 Financial Results
GlobeNewswire - Mon Mar 23, 3:05PM CDT
-- Strong cash position bolstered through IPO and follow-on financing, raising a combined total of over $173 million
FLXN: 18.77 (-0.78)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 18.77 (-0.78), MDT: 78.01 (+0.93), RARE: 66.96 (+2.74), PFE: 34.93 (+0.04), SUPN: 13.67 (-0.10), NRX: 8.00 (-0.27), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), SVA: 5.06 (+0.10), BLRX: 2.12 (unch), AMPH: 15.08 (-0.13), CHRS: 24.79 (-0.89), JNJ: 100.43 (+0.13), GNVC: 2.86 (-0.11), CYCC: 0.94 (-0.03), AZN: 73.35 (+0.65), DPRX: 12.73 (+0.13), TEVA: 63.01 (-1.15), NBY: 0.66 (-0.01)
Tinnitus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Mar 17, 11:30AM CDT
The report "Tinnitus - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tinnitus. Tinnitus is the medical term for "hearing" noises in your ears when there is no outside source of the sounds. It can make verbal communication impossible and can cause depression. Depending on the type of tinnitus, symptoms will tend to come and go over time. Stress level, diet, and exposure to noise can worsen tinnitus. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tinnitus-pip...eport.html .
FLXN: 18.77 (-0.78), EARS: 4.65 (-0.75), OTIC: 32.83 (unch)
Flexion Therapeutics to Report Year-End 2014 Earnings Results on March 23, 2015
GlobeNewswire - Mon Mar 16, 3:05PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its year-end 2014 financial results on Monday, March 23, 2015, at 4:30 p.m. ET.
FLXN: 18.77 (-0.78)
Flexion Therapeutics reports changes in board members
M2 - Mon Mar 09, 5:17AM CDT
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) revealed on Friday the addition of Scott Canute to its board of directors with effect from 4 March 2015.
FLXN: 18.77 (-0.78)
Post-Operative Pain - Pipeline Review, H1 2015 - 32 Companies & 42 Drug Profiles
M2 - Tue Mar 03, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9l5kz/postoperative) has announced the addition of the "Post-Operative Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AngioChem Inc. - Boehringer Ingelheim GmbH - Cara Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - Cytogel Pharma, LLC - DURECT Corporation - Echo Pharmaceuticals B.V. - Encore Therapeutics Inc. - Flexion Therapeutics, Inc. - Galleon Pharmaceuticals - Grunenthal GmbH - GW Pharmaceuticals plc - Heron Therapeutics, Inc. - Immupharma Plc - INSYS Therapeutics, Inc. - Laboratorios Del Dr. Esteve S.A. - Medtronic, Inc. - Ocular Therapeutix, Inc. - Omeros Corporation - Orbis Biosciences, Inc. - Orion Oyj - Pharmazz, Inc. - PhytoHealth Corporation - Recro Pharma, Inc. - Rottapharm SpA - Takeda Pharmaceutical Company Limited - Thar Pharmaceuticals, Inc. Drug Profiles - (bupivacaine hydrochloride meloxicam) - (dexketoprofen trometamol tramadol hydrochloride) - (ketoprofen amitriptyline oxymetazoline) - (ketorolac tromethamine phenylephrine hydrochloride) - AM-4 - ANG-2002 - ARX-01 - ARX-8028 - ARX-8203 - AYX-1 - BI-1026706 - bupivacaine hydrochloride - bupivacaine hydrochloride liposomal - bupivacaine hydrochloride SR - buprenorphine hydrochloride - centhaquine - CKD-943 - CMX-020 - CR-4056 - CR-845 - Cyt-1010 - dexamethasone acetate SR - dexmedetomidine hydrochloride - dronabinol - E-52862 - fadolmidine hydrochloride - FX-007 - GAL-044 - GIBH-1014 For more information visit http://www.researchandmarkets.com/research/b9...toperative
ACRX: 4.50 (-0.07), INSY: 62.10 (+0.76), FLXN: 18.77 (-0.78), MDT: 78.01 (+0.93), HRTX: 14.17 (-0.02), DRRX: 2.19 (+0.10), REPH: 10.71 (-0.78), OMER: 24.41 (-0.15), OCUL: 25.90 (-0.05)
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 18.77 (-0.78), EBS: 29.84 (-0.13), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21), AZN: 73.35 (+0.65), CCXI: 7.86 (-0.02), ATHX: 1.34 (+0.01), CELGZ: 2.87 (+0.04)
Flexion Therapeutics to Present at RBC Capital Markets Healthcare Conference
GlobeNewswire - Tue Feb 17, 8:50AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015 at 9:00 a.m. Eastern Time at The New York Palace Hotel in New York, NY.
FLXN: 18.77 (-0.78)
3 Stocks Spiking on Big Volume: Baidu, LogMeIn and Flexion
at The Street - Fri Feb 13, 12:26PM CST
Keep these stocks rising on unusual volume on your trading radar.
FLXN: 18.77 (-0.78), BIDU: 213.37 (+0.52), LOGM: 58.19 (-0.16)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), CBYL: 7.02 (-0.38), ANIK: 38.68 (+0.05)
Flexion Therapeutics begins Phase 3 clinical trial of FX006 for osteoarthritis of the knee
M2 - Tue Feb 03, 8:26PM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) said on Monday that it has dosed the first patient with osteoarthritis (OA) of the knee under its Phase 3 clinical trial of its lead drug candidate FX006.
FLXN: 18.77 (-0.78)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), CBYL: 7.02 (-0.38), ANIK: 38.68 (+0.05)
Flexion Therapeutics Initiates Phase 3 Clinical Trial of FX006 in Patients With Osteoarthritis of the Knee
GlobeNewswire - Mon Feb 02, 3:11PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced dosing of the first patient in the Phase 3 clinical trial of its lead drug candidate FX006 as a treatment for pain associated with osteoarthritis (OA) of the knee. FX006 is Flexion's novel, non-opioid, sustained-release, intra-articular (IA or within the joint) formulation of triamcinolone acetonide (TCA). FX006 is designed for patients with moderate to severe OA pain and is intended to provide substantial and persistent pain relief while avoiding systemic side effects.
FLXN: 18.77 (-0.78)
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 17, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
FLXN: 18.77 (-0.78), NDQ.TO: 15.30 (-0.49), XPLR: 6.14 (-0.04), JOUT: 32.20 (-0.19), NVDQ: 12.43 (-0.37), SPKE: 12.97 (+0.09)
Flexion Therapeutics to Present at 14th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 08, 7:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:50 a.m. Eastern Time at The Westin NY Grand Central Hotel in New York, NY.
FLXN: 18.77 (-0.78)
Flexion Therapeutics reports FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 5:51AM CDT
FLXN: 18.77 (-0.78)
Flexion Therapeutics' (FLXN) CEO Mike Clayman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 23, 9:13PM CDT
FLXN: 18.77 (-0.78)
Flexion Reports Year-End 2014 Financial Results
GlobeNewswire - Mon Mar 23, 3:05PM CDT
-- Strong cash position bolstered through IPO and follow-on financing, raising a combined total of over $173 million
FLXN: 18.77 (-0.78)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 18.77 (-0.78), MDT: 78.01 (+0.93), RARE: 66.96 (+2.74), PFE: 34.93 (+0.04), SUPN: 13.67 (-0.10), NRX: 8.00 (-0.27), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), SVA: 5.06 (+0.10), BLRX: 2.12 (unch), AMPH: 15.08 (-0.13), CHRS: 24.79 (-0.89), JNJ: 100.43 (+0.13), GNVC: 2.86 (-0.11), CYCC: 0.94 (-0.03), AZN: 73.35 (+0.65), DPRX: 12.73 (+0.13), TEVA: 63.01 (-1.15), NBY: 0.66 (-0.01)
Tinnitus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Mar 17, 11:30AM CDT
The report "Tinnitus - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tinnitus. Tinnitus is the medical term for "hearing" noises in your ears when there is no outside source of the sounds. It can make verbal communication impossible and can cause depression. Depending on the type of tinnitus, symptoms will tend to come and go over time. Stress level, diet, and exposure to noise can worsen tinnitus. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tinnitus-pip...eport.html .
FLXN: 18.77 (-0.78), EARS: 4.65 (-0.75), OTIC: 32.83 (unch)
Flexion Therapeutics to Report Year-End 2014 Earnings Results on March 23, 2015
GlobeNewswire - Mon Mar 16, 3:05PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its year-end 2014 financial results on Monday, March 23, 2015, at 4:30 p.m. ET.
FLXN: 18.77 (-0.78)
Flexion Therapeutics reports changes in board members
M2 - Mon Mar 09, 5:17AM CDT
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) revealed on Friday the addition of Scott Canute to its board of directors with effect from 4 March 2015.
FLXN: 18.77 (-0.78)
Post-Operative Pain - Pipeline Review, H1 2015 - 32 Companies & 42 Drug Profiles
M2 - Tue Mar 03, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9l5kz/postoperative) has announced the addition of the "Post-Operative Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AngioChem Inc. - Boehringer Ingelheim GmbH - Cara Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - Cytogel Pharma, LLC - DURECT Corporation - Echo Pharmaceuticals B.V. - Encore Therapeutics Inc. - Flexion Therapeutics, Inc. - Galleon Pharmaceuticals - Grunenthal GmbH - GW Pharmaceuticals plc - Heron Therapeutics, Inc. - Immupharma Plc - INSYS Therapeutics, Inc. - Laboratorios Del Dr. Esteve S.A. - Medtronic, Inc. - Ocular Therapeutix, Inc. - Omeros Corporation - Orbis Biosciences, Inc. - Orion Oyj - Pharmazz, Inc. - PhytoHealth Corporation - Recro Pharma, Inc. - Rottapharm SpA - Takeda Pharmaceutical Company Limited - Thar Pharmaceuticals, Inc. Drug Profiles - (bupivacaine hydrochloride meloxicam) - (dexketoprofen trometamol tramadol hydrochloride) - (ketoprofen amitriptyline oxymetazoline) - (ketorolac tromethamine phenylephrine hydrochloride) - AM-4 - ANG-2002 - ARX-01 - ARX-8028 - ARX-8203 - AYX-1 - BI-1026706 - bupivacaine hydrochloride - bupivacaine hydrochloride liposomal - bupivacaine hydrochloride SR - buprenorphine hydrochloride - centhaquine - CKD-943 - CMX-020 - CR-4056 - CR-845 - Cyt-1010 - dexamethasone acetate SR - dexmedetomidine hydrochloride - dronabinol - E-52862 - fadolmidine hydrochloride - FX-007 - GAL-044 - GIBH-1014 For more information visit http://www.researchandmarkets.com/research/b9...toperative
ACRX: 4.50 (-0.07), INSY: 62.10 (+0.76), FLXN: 18.77 (-0.78), MDT: 78.01 (+0.93), HRTX: 14.17 (-0.02), DRRX: 2.19 (+0.10), REPH: 10.71 (-0.78), OMER: 24.41 (-0.15), OCUL: 25.90 (-0.05)
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 18.77 (-0.78), EBS: 29.84 (-0.13), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21), AZN: 73.35 (+0.65), CCXI: 7.86 (-0.02), ATHX: 1.34 (+0.01), CELGZ: 2.87 (+0.04)
Flexion Therapeutics to Present at RBC Capital Markets Healthcare Conference
GlobeNewswire - Tue Feb 17, 8:50AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015 at 9:00 a.m. Eastern Time at The New York Palace Hotel in New York, NY.
FLXN: 18.77 (-0.78)
3 Stocks Spiking on Big Volume: Baidu, LogMeIn and Flexion
at The Street - Fri Feb 13, 12:26PM CST
Keep these stocks rising on unusual volume on your trading radar.
FLXN: 18.77 (-0.78), BIDU: 213.37 (+0.52), LOGM: 58.19 (-0.16)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), CBYL: 7.02 (-0.38), ANIK: 38.68 (+0.05)
Flexion Therapeutics begins Phase 3 clinical trial of FX006 for osteoarthritis of the knee
M2 - Tue Feb 03, 8:26PM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) said on Monday that it has dosed the first patient with osteoarthritis (OA) of the knee under its Phase 3 clinical trial of its lead drug candidate FX006.
FLXN: 18.77 (-0.78)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), CBYL: 7.02 (-0.38), ANIK: 38.68 (+0.05)
Flexion Therapeutics Initiates Phase 3 Clinical Trial of FX006 in Patients With Osteoarthritis of the Knee
GlobeNewswire - Mon Feb 02, 3:11PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced dosing of the first patient in the Phase 3 clinical trial of its lead drug candidate FX006 as a treatment for pain associated with osteoarthritis (OA) of the knee. FX006 is Flexion's novel, non-opioid, sustained-release, intra-articular (IA or within the joint) formulation of triamcinolone acetonide (TCA). FX006 is designed for patients with moderate to severe OA pain and is intended to provide substantial and persistent pain relief while avoiding systemic side effects.
FLXN: 18.77 (-0.78)
